Molecular Partners Ag (MOLN) Current Deferred Revenue (2020 - 2024)
Molecular Partners Ag (MOLN) posted quarterly Current Deferred Revenue of $646889.2 for Q2 2024, down 90.04% year-over-year from $6.5 million in Q3 2023, and up 29523.94% quarter-over-quarter from $2183.7 in Q1 2024.
Molecular Partners Ag (MOLN) Current Deferred Revenue (2020 - 2024) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Current Deferred Revenue for 5 consecutive years, with $646889.2 the latest figure, recorded in Q2 2024.
- In Q2 2024, Current Deferred Revenue fell 90.04% year-over-year to $646889.2; the TTM figure through Jun 2024 stood at $646889.2 (down 90.04% YoY), while the FY2023 annual figure was $4.9 million, down 53.16% from the prior year.
- Current Deferred Revenue climbed to $646889.2 in Q2 2024 per MOLN's latest filing, from $2183.7 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $50.8 million in Q4 2020 and bottomed at $2183.7 in Q1 2024.
- Historically, Current Deferred Revenue has averaged $9.3 million across 5 years, with a median of $646889.2 in 2024.
- Annual changes were most pronounced in 2021 — Current Deferred Revenue dropped 24.71% — and 2024, when it plunged 90.04%.
- Molecular Partners Ag's Current Deferred Revenue stood at $50.8 million in 2020, then decreased by 24.71% to $38.2 million in 2021, then slumped by 72.71% to $10.4 million in 2022, then plunged by 53.16% to $4.9 million in 2023, then slumped by 86.76% to $646889.2 in 2024.
- Business Quant data shows MOLN's Current Deferred Revenue at $646889.2 in Q2 2024, $2183.7 in Q1 2024, and $4.9 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.81 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.30 Bn | 60.11 Bn | 1.37 Bn |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.77 Bn | 28.46 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.32 Bn | - |
| 10 | Molecular Partners Ag | 163.25 Mn | 163.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 646,889.19 |
| Mar 31, 2024 | 2,183.67 |
| Dec 31, 2023 | 4.88 Mn |
| Sep 30, 2023 | 4,790.14 |
| Jun 30, 2023 | 6.49 Mn |
| Mar 31, 2023 | 6,979.99 |
| Dec 31, 2022 | 10.43 Mn |
| Sep 30, 2022 | 8,244.31 |
| Jun 30, 2022 | 9.36 Mn |
| Mar 31, 2022 | 19,422.33 |
| Dec 31, 2021 | 38.21 Mn |
| Sep 30, 2021 | 28,030.92 |
| Dec 31, 2020 | 50.76 Mn |